Talea Group (TALEA) Fair Value & Analysis

Healthcare · IT · Market cap €40.7M

Below-average quality, and screening another 76% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (€2.13). The favourable scenario is already priced in.
• Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The model range is unusually wide (€0.2295 to €2.13). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.

How to read this chart

60‑month range €3.27 – €35.00 · fair‑value band €0.2295 – €2.13 · the €4.80 price screens above the €1.15 fair value. Dashed = 300-day average. As of Jul 25, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Talea Group (TALEA) currently trades at €4.80, while our model-based Fair Value estimate is €1.15, implying the stock looks roughly 76.1% overvalued today. The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Talea Group generated revenue of €132M at a net margin of -2.5%. Revenue declined 19.5% year over year. It earns a return on equity of -9.9%. Net debt stands at €27.3M. Fundamentals as of Jul 25, 2026

Our scenario range runs from €0.2295 (bear case) to €2.13 (bull case); at €4.80, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 59% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -76%, TALEA screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (€2.74) versus DCF Models (€0.9500). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Talea Group S.p.A. operates as an e-retailer of health, wellness, and beauty products in Italy. It operates through two segments: Consumers Area and Industrial Area.

Full company description

Talea Group S.p.A. operates as an e-retailer of health, wellness, and beauty products in Italy. It operates through two segments: Consumers Area and Industrial Area. The Consumer Area segment offers cosmetics; hair products; skincare; make up and fragrances; supplements/dietary products; over-the-counter medicines; medical devices; electromedical equipment; hygiene and wellness; mother- and child-care; homeopathic and herbal care products; healthcare products; orthopaedic and health aids; and pet care and nutrition products under the Farmaè, Amicafarmacia, Farmaeurope, Beautyè, and Sanort brand names. Its Industrial Area segment provides digital communication and marketing services under the Valnan brand, as well as manages an ecosystem of digital opportunities for companies through consulting, data analysis, creativity, digital marketing, and data economy services under the Talea Media brand. The company was formerly known as Farmaè S.p.A. and changed its name to Talea Group S.p.A. in May 2023. Talea Group S.p.A. was founded in 2014 and is based in Viareggio, Italy.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Talea Group reported revenue of €132M in FY2024 versus €64.1M in FY2020, a compound +19.8%/yr. Reported net income was −€3.2M in FY2024.

TALEA screens 76% overvalued. Compare with JD Health International Inc →

Peer Group

Pharmaceutical Retailers · 61 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.